OXIGENE, INC.

Company

Oncotelic Therapeutics, Inc.

Filed

April 28, 2006

Period of Report

June 14, 2006

Accession Number

0000950135-06-002812

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →